OptimizeRx Q4 2021 Earnings Report
Key Takeaways
OptimizeRx reported a 24% increase in Q4 revenue to $20.3 million compared to the same period in 2020. The company's gross margin increased to 61%. GAAP net income was $0.6 million, or $0.04 per basic share, while non-GAAP net income was $4.0 million, or $0.23 per basic share. OptimizeRx ended the quarter with $84.7 million in cash and cash equivalents.
Total revenue increased by 24% to $20.3 million compared to the same period in 2020.
Gross margin increased to 61% due to solution and channel mix.
GAAP net income was $0.6 million, or $0.04 per basic share.
Non-GAAP net income was $4.0 million, or $0.23 per basic share.
OptimizeRx
OptimizeRx
Forward Guidance
For the full year 2022, the Company expects net revenues of $80 million to $85 million, representing year-over-year growth of 31% to 39%, respectively. Gross margins for 2022 are expected to be relatively constant year-over-year and are expected to come in between 57% and 60%.